Srinivas Sridhar, PhDNortheastern University Targeted PARP Inhibitor Nanotherapy for Ovarian Cancer PARP inhibitor therapy has shown promising results in clinical trials for ovarian cancer, but oral administration of these drugs requires high doses leading to toxic side effects, and very little drug actually reaches the tumors. Dr. Sridhar and colleagues have synthesized nano-scale formulations of […]
Read More
Jason Wilken, PhDYale University sErb83: A novel ovarian cancer prognostic biomarker A well-studied growth regulator in the development of ovarian cancer is the “oncogene” known as ErbB3/HER-3. There are several naturally-occurring variants of ErbB3 which are difficult to distinguish by currently available methods. We believe that developing accurate and specific tests for each ErbB3 variant […]
Read More
Toshi Taniguchi, MD, PhDFred Hutchinson Cancer Research Center Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, […]
Read More
Janet Sawicki, PhDLankenau Institute for Medical Research Utilizing HuR to Combat Chemotherapeutic Resistance in Ovarian Cancer The molecular basis underlying the range of ovarian cancer patient responses to chemotherapeutic agents is poorly understood. This project will address the urgent need to stratify ovarian cancer patients for therapy and enhance currently available treatment strategies. Recently, Dr. […]
Read More
Jeremy Stark, PhDBeckman Research Institute of the City of Hope Homology-Directed Repair Deficiency in Ovarian Cancer Cancer cells that are able to perform homology-directed repair (HDR) can be resistant to PARP inhibitor therapeutics, which are purposefully designed to cause DNA damage. Many ovarian cancers apparently lack the HDR pathway, and hence are likely to be […]
Read More
Bin Zhang, MD, PhDNorthwestern University Treating ovarian cancer with novel ecto-5’nucleotidase (CD73) inhibitors Tumors have elaborate suppressive mechanisms against host immune system to enhance their survival. Ovarian tumors highly express a protein called CD73 that limits anti-tumor immune response in order to promote tumor growth. Dr. Zhang‘s recent research demonstrates that CD73 may serve as […]
Read More
Lilie Lin, MDUniversity of Pennsylvania School of Medicine Pilot study of a novel PARP inhibitor PET tracer in patients with ovarian carcinoma Targeted agents such as poly-ADP ribose polymerase (PARP) inhibitors are actively being tested alone or in combination with chemotherapy or radiotherapy as promising treatments for ovarian cancer. However, not all patients will respond […]
Read More
Andrew Wilson, PhDVanderbilt University Prognostic Significance of TR3/NR4A1 Expression in Ovarian Cancer A key clinical problem in the management of advanced ovarian cancer is tumor resistance to traditional platinum drugs and to newer drugs that inhibit the PARP protein (PARPi). Dr. Wilson will investigate an innovative approach to improve the effects of platinum drugs and […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center Overcoming acquired resistance to antiangiogenic therapy by targeting vascular p130cas Angiogenesis, the process of forming a new network of blood vessels from existing ones, is a central hallmark of cancer. In order for a tumor to grow, it must have the blood flow necessary to feed […]
Read More
Carlos Telleria, PhDMcGill University Health Center Proteotoxic Stress Therapy in Ovarian Cancer The majority of ovarian cancers recur 18-24 months after first responding to chemotherapy. Residual cells hide out in the abdominal cavity and often become unresponsive to current chemotherapy when they grow back. Dr. Telleria researches therapies that would be administered chronically after chemotherapy […]
Read More